Revolutionary New Dementia Drug
Charsire has patented technology that controls human cellular inflammation and platelet-derived growth factors. Our new drug BAC for Alzheimer’s disease and vascular dementia has completed the Phase II clinical validation of the US Food and Drug Administration (FDA), providing the best overall efficacy for dementia patients around the world. Phase III clinical trials are underway. In addition, we have completed the clinical validation of diabetic foot ulcers and cancer radiodermatitis, and obtained the approval of Taiwan’s Class II medical device.